Table 2.

Clinicopathologic significance of the CD47/GAPDH mRNA expression ratio in bone marrow and in peripheral blood

CD47/GAPDH clinicopathologic factorsBMPB
Low ratio (%)High ratio (%)PLow ratio (%)High ratio (%)P
Age, y (mean ± SD)55.7 ± 11.255.1 ± 11.5n.s.55.8 ± 10.954.9 ± 11.8n.s.
Menopause status0.01*n.s.
    Pre71 (31.4)96 (42.5)76 (33.6)91 (40.3)
    Post155 (68.6)130 (57.5)150 (66.4)135 (59.7)
Tumor stagen.s.0.0011*
    T1103 (45.6)123 (54.4)96 (42.8)130 (57.2)
    T2-4123 (54.4)103 (45.6)130 (57.2)96 (42.8)
Lymph node metastasisn.s.n.s.
    Absent138 (61.1)137 (60.6)135 (59.7)140 (61.9)
    Present88 (38.9)89 (39.4)91 (40.3)86 (38.1)
Lymphatic invasionn.s.n.s.
    Absent127 (56.2)146 (64.6)130 (58.0)143 (62.3)
    Present99 (43.8)80 (35.4)96 (42.0)83 (36.7)
Venous invasionn.s.n.s.
    Absent215 (95.1)208 (92.0)215 (95.1)208 (92.0)
    Present11 (4.9)18 (8.0)11 (4.9)18 (8.0)
Distant metastasisn.s.n.s.
    Absent221 (97.8)222 (98.2)221 (98.2)222 (97.8)
    Present5 (2.2)4 (1.8)5 (1.8)4 (2.2)
Stagen.s.n.s.
    Stage I78 (34.5)86 (38.1)73 (32.3)91 (40.7)
    Stage II-IV148 (65.5)140 (62)153 (67.7)135 (59.3)
ERn.s.n.s.
    Absent56 (24.8)74 (32.7)68 (30.1)62 (27.0)
    Present170 (75.2)152 (67.3)158 (69.9)164 (73.0)
PgRn.s.n.s.
    Absent102 (45.1)101 (44.7)95 (42.0)108 (47.8)
    Present124 (54.9)125 (55.3)131 (58.0)118 (52.2)
Her2 score0.03*n.s.
    0-1157 (69.5)135 (59.7)152 (67.3)140 (61.9)
    2-369 (30.5)91 (40.3)74 (32.7)86 (38.1)
ER, PgR, Her2 status0.0097*n.s.
    Triple negative26 (11.5)46 (20.4)26 (11.5)46 (20.4)
    Either one positive200 (88.5)180 (79.7)200 (88.5)180 (79.7)
Recurrence0.04*<0.0001*
    Absent189 (83.6)204 (90.3)181 (80.1)212 (93.8)
    Present37 (16.4)22 (9.7)45 (19.9)14 (6.2)

Abbreviation: n.s., not significant.

  • *P < 0.05, statistical significance.